Blade Air Mobility, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 09, 2023 at 08:29 am EDT
Share
Blade Air Mobility, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was USD 60.99 million compared to USD 35.63 million a year ago. Net loss was USD 12.23 million compared to net income of USD 8.41 million a year ago. Basic loss per share from continuing operations was USD 0.17 compared to basic earnings per share from continuing operations of USD 0.11 a year ago. Diluted loss per share from continuing operations was USD 0.17 compared to diluted earnings per share from continuing operations of USD 0.1 a year ago.
For the six months, sales was USD 106.26 million compared to USD 62.26 million a year ago. Net loss was USD 22.42 million compared to USD 2.6 million a year ago. Basic loss per share from continuing operations was USD 0.31 compared to USD 0.04 a year ago. Diluted loss per share from continuing operations was USD 0.31 compared to USD 0.04 a year ago.
Blade Air Mobility, Inc. provides air transportation and logistics for hospitals across the United States. The Company transports human organs for transplant, and for passengers, with helicopter and fixed wing services primarily in the Northeast United States, Southern Europe and Western Canada. The Company's segments include Passenger and Medical. Its Passenger segment includes Short Distance and Jet and Other. Short Distance business consists primarily of helicopter and amphibious seaplane flights in the United States, Canada and Europe. Jet and Other business consist principally of non-medical jet charter and by-the-seat jet flights between New York and South Florida. Its Medical segment includes MediMobility Organ Transport, which consists primarily of transportation of human organs for transplant and/or the medical teams supporting these services. It also offers additional services including donor logistics coordination and support for evaluating potential donor organs.